Biosimilars Drugs Marketing 
Drug Channels
JANUARY 28, 2022
Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. It's a moderated discussion with payers on how the changing market might impact their management strategies in immunology.
Drug Channels
SEPTEMBER 7, 2022
As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. That’s when Humira, the best-selling drug in the U.S., will face multiple biosimilar competitors. d/b/a Drug Channels Institute.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
DrugBank
SEPTEMBER 26, 2024
Biosimilars Biosimilars, while highly similar to their reference biopharmaceuticals, offer distinct advantages that position them as preferred therapeutic options in many cases. This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles.
Drug Channels
OCTOBER 3, 2023
Since I published the article below in July 2023 , there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of Amgen's Amjevita, the first Humira biosimilar. Boehringer-Ingelheim launched an unbranded, low WAC version of its interchangeable biosimilar.
Drug Channels
JULY 18, 2023
The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies. d/b/a Drug Channels Institute.
Drug Channels
OCTOBER 6, 2020
The biosimilar market is finally beginning to fulfill its promise. The latest data show that provider-administered biosimilar drugs are successfully displacing their reference biological products. As I predicted last year, newer biosimilars are being adopted quickly, and their prices are declining rapidly.
Drug Channels
FEBRUARY 7, 2023
As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Our crazy drug channel led Amgen to launch both a high-list/high-rebate and a low-list/low-rebate version of the drug. d/b/a Drug Channels Institute. This Feed is for personal non-commercial use only.
Expert insights. Personalized for you.
80 
Let's personalize your content